Sign up United Kingdom
Proactive Investors - Run By Investors For Investors
Markets

Lloyds Banking looking to put its trials behind it

PPI, the HBOS acquisition and now the prospect of a rate rise hitting the mortgage market; it's all a bit of a trial for Lloyds
Lloyds Bank Black Horse
Lloyds opens the batting in banking results season

Lloyds Banking Group PLC (LON:LLOY) will be the first of the London-listed banks to report its third quarter results this month.

Investors will be keen to see whether the bank has been able to shrug off its ongoing legacy issues to deliver further growth.

In July the group reported is biggest half-year profits in eight years; however, the company is continuing to tackle compensation claims related to its payment protection insurance (PPI) mis-selling scandal and has set aside more than £18bn in provisions.

The market will be paying close attention on any further costs relating to PPI claims in the third quarter update on Wednesday.  Adding to its legal dramas, a trial brought against the bank by shareholders over its ill-fated takeover of HBOS in 2008 has started in the high court.

“Lloyds’ ability to step up the dividend could be a trigger for a re-rating, but regulatory change has muddied the waters on this recently. Although we don’t expect clarity until full year results in February 2018, we expect this to be a key topic of discussion with management,” said Rohith Chandra-Rajan at Barclays.

“In terms of operational performance, mortgage pricing has remained under pressure, but we expect offsets from lower funding costs to support the net interest margin. We will also look for delivery on Lloyds’ ability to begin growing its prime UK mortgage book.

“Little appears to have changed from a credit quality perspective so we expect the provision charge to remain low,” the analyst added.

“On non-operating issues, early experience of PPI claims after the two year time bar was triggered will be the key influence on any additional provisions.”

Consumer healthcare and respiratory pricing the hot topics at Glaxo

Given the recent weak performance of Reckitt Benckiser Group PLC’s (LON:RB.) health division and rumours that both Pfizer Inc (NYSE:PFE) and Merck & Co Inc (NYSE:MRK) are looking to sell off their consumer businesses, GlaxoSmithKline plc’s (LON:GSK) consumer healthcare arm will be in focus in Wednesday’s third quarter update.

As the former head of that business, new chief executive Emma Walmsley will also have a particular interest in how it’s faring.

A solid performance over the past three months would not only bode well for the current brands – which include Sensodyne and Nicorette – but could also fuel rumours that GSK is on the lookout for some of its rivals’ unwanted assets.

Elsewhere, keep an eye out for another healthy performance from the FTSE 100 group’s HIV treatments Tivicay and Triumeq, as well as continued growth from new respiratory products to help offset declines in Advair and Seretide.

“Commentary at the Q2 results on respiratory pricing was bearish; however, the facts are that: (i) management confirmed, not cut, long range guidance for flat or better respiratory sales 2015-20 even with generic Advair, and (ii) estimates already assume heavy price cuts even for the new respiratory products,” opined Liberum’s healthcare team, which thinks Glaxo’s shares have fallen far enough.

Significant announcements expected

Trading updates: Antofagasta (Q3), GlaxoSmithKline plc (Q3) (LON:GSK), Lombard Risk Management plc (LON:LRM),  Metro Bank PLC (LON:MTRO), Centaur Media PLC (LON:CAU), Cobham PLC (LON:COB), Lloyds Banking Group PLC (LON:LLOY)

Economic data: Second reading UK Q3 GDP; BBA UK mortgage lending data; German IFO business climate survey; US durable goods orders; US new home sales


No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use